Last reviewed · How we verify
Flaxseed
At a glance
| Generic name | Flaxseed |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food (NA)
- ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults (PHASE2)
- Impact of Seed Cycling on Menstrual Regularity, Dysmenorrhea, and Premenstrual Symptoms (NA)
- Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease (NA)
- Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausal Women (NA)
- Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia (NA)
- Effects of Different Dietary Models on Eating Behavior and Obesity Management in Overweight and Obese Individuals (NA)
- Impact of Vaccenic Acid Consumption on the Metabolism of Saturated Fatty Acids: Relationship With Cardiovascular Risk Factors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flaxseed CI brief — competitive landscape report
- Flaxseed updates RSS · CI watch RSS
- Mayo Clinic portfolio CI